TTK Healthcare is currently trading at Rs. 517.00, up by 31.95 points or 6.59% from its previous closing of Rs. 485.05 on the BSE.
The scrip opened at Rs. 490.00 and has touched a high and low of Rs. 542.80 and Rs. 490.00 respectively. So far 56804 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 598.00 on 12-Dec-2012 and a 52 week low of Rs. 330.35 on 16-May-2012.
Last one week high and low of the scrip stood at Rs. 542.80 and Rs. 456.50 respectively. The current market cap of the company is Rs. 403.83 crore.
The promoters holding in the company stood at 65.43% while Institutions and Non-Institutions held 4.40% and 30.18% respectively.
TTK Healthcare has received an approval for scheme of amalgamation of TTK Protective Devices (TTKPD) (formerly known as TTK-LlG), an unlisted public company and TSL Techno Services (TSL), a wholly owned subsidiary of TTK Protective Devices (TTKPD) with itself.
On amalgamation of the companies, the shareholders of TTKPD will be entitled to 9 equity shares of Rs 10 each fully paid-up of the company (TTK Healthcare), for every 2 of Rs 10 each fully paid-up held by them in TTKPD. Further, no allotment shall be made to the shareholders of TSL Techno Services, it being the wholly owned subsidiary of TTKPD, the value of TSL having already been considered as part of the Valuation of TTKPD.
The Scheme will take effect after necessary approvals from regulatory authorities, shareholders of the respective Companies and the High Court of Judicature at Madras. The board of company at its meeting held on April 30, 2013 has approved for the same.
TTK Healthcare brand wagon consists of products that are sought after by a wide range of customers. It has an all India sales and distribution network for marketing not only their own products, but also the KIWI Brand (Shoecare), Brylcreem (Haircare) and Kohinoor and Durex brands (Contraceptives).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1462.50 |
| Dr. Reddys Lab | 5784.50 |
| Cipla | 1451.25 |
| Zydus Lifesciences | 1001.15 |
| Lupin | 1587.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
